Monday 1 July 2024

The Pharma Letter Podcast — Episode 20 — Galapagos update—with CEO Paul Stoffels

Biotechnology
Simon Wentworth
2 February 2023
2-2

More on this story...

Biotechnology
R&D U-turn sees Galapagos ditching liver and kidney programs
4 November 2022
Biotechnology
Belgian biotech Galapagos goes on a spending spree
22 June 2022
Biotechnology
NICE recommends Galapagos' Jyseleca in UC
1 June 2022
Biotechnology
Strategic overhaul continues apace at Galapagos, with new R&D deal
31 March 2023


Related Company News

EMA/CHMP June 2024 meeting highlights
ASCO 2024: Positive Phase III results for Sanofi’s Sarclisa could challenge Darzalex
Contineum files for IPO
Galapagos invests in early pipeline with small molecule partnership
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze